VNRX Earnings Prediction
The chart below shows how VNRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VNRX sees a +12.80% change in stock price 10 days leading up to the earnings, and a +3.23% change 10 days following the report. On the earnings day itself, the stock moves by -2.17%. This data can give you a slight idea of what to expect for the next quarter's release.
VNRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
474.52K
187.22%
19.89%
Gross Margin
--
--
--
Operating Margin
-1236.76%
-76.39%
-29.97%
Net Margin
-1236.73%
-75.83%
-30.67%
EPS
-0.07
-36.36%
-12.50%
No Data Available
VNRX Earnings Analysis
VolitionRX Limited Common Stock Corporation (VNRX.A) Earnings Conference Call
Positive
Nu.Q Vet Sales Surge: In the first three quarters of 2024, VolitionRx sold over 110,000 Nu.Q Vet cancer tests, significantly surpassing the 58,000 sold in the entire previous year, 2023.
Record Revenue Surge: Year-to-date revenue growth reached 100%, with a remarkable 307% increase in revenue for the third quarter compared to the same period in 2023.
Veterinary Kits Revenue Growth: The revenue from veterinary kits' key components is approximately $730,000, indicating strong market demand.
Cost Management Success: Operating expenses were reduced by 28% compared to the same quarter last year, showcasing effective cost management strategies.
Operating Activities Cash Flow: Cash used in operating activities was $5.4 million in the third quarter of 2024, down 36% year-on-year, reflecting improved operational efficiency.
Negative
Revenue Growth Slowdown: In 2024, the company recorded $1 million in revenue for the nine-month period ending September 30, a growth of only 96% over the same period of 2023, indicating a slowdown in growth compared to previous quarters.
Cost Reduction Impact: Operating expenses were down 36% year-on-year, reflecting significant cost-cutting measures that may impact future operational capabilities.
Revenue Growth Concerns: Despite a 307% increase in revenue for the third quarter compared to the prior year, the overall revenue growth rate has shown signs of deceleration, raising concerns about sustainability.
Licensing Deal Limitations: The company has not yet secured any significant licensing deals in the human health space, which could limit future revenue opportunities.
Distributor Dependency Risk: The reliance on a limited number of distributors across 17 countries poses a risk to revenue stability, as any disruptions could significantly impact sales.
VNRX FAQs
How does VNRX typically perform around its earnings report dates?
Is VolitionRx Limited (VNRX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VNRX Earning Call Sentiment
VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VNRX.A
-4.4%Positive
The earnings call summary indicates strong revenue growth, significant cost reductions, and a clear path towards cash neutrality by 2025. The Q&A section provides additional insights, such as a strong market presence in Japan and expected operational expense reductions. Although there are competitive pressures and funding risks, the company's positive financial metrics and optimistic future outlook suggest a positive stock price movement over the next two weeks.
